Brent Sabatini Sells 1,562 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,562 shares of Vir Biotechnology stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $9.15, for a total value of $14,292.30. Following the completion of the transaction, the chief accounting officer now owns 28,189 shares of the company's stock, valued at approximately $257,929.35. This trade represents a 5.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR traded up $0.04 during trading on Tuesday, reaching $9.69. 928,477 shares of the company were exchanged, compared to its average volume of 2,851,883. The business's fifty day simple moving average is $9.18 and its 200-day simple moving average is $8.46. Vir Biotechnology, Inc. has a 12-month low of $6.56 and a 12-month high of $14.45. The firm has a market capitalization of $1.33 billion, a PE ratio of -2.47 and a beta of 0.64.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Blue Trust Inc. grew its position in shares of Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after buying an additional 2,351 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Vir Biotechnology during the 4th quarter worth about $42,000. nVerses Capital LLC bought a new position in Vir Biotechnology during the 3rd quarter worth about $56,000. SBI Securities Co. Ltd. purchased a new position in Vir Biotechnology during the 4th quarter valued at about $60,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock valued at $61,000 after purchasing an additional 1,999 shares in the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on VIR. Morgan Stanley raised shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Barclays reduced their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. boosted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research report on Thursday, January 9th. Leerink Partners increased their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Finally, HC Wainwright reissued a "buy" rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, January 31st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.83.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).